comprehensive -WSS

comprehensive

author：entertainment 2025-08-19 15:01:56 - browse：33

Adam's take main illustration — Molly Ferguson/STAT

Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics:

A take-under deal feels meh for biotech sector sentiment.Bristol is paying $58 per share in cash for Mirati, which closed Friday at $60. Granted, Mirati was trading in the $30 range in September, so from there, the roughly 50% premium isn’t terrible. But as Mizuho strategist Jared Holz pointed out, investors would liked to have seen Mirati go for $75-$100 per share.

With the closely watched XBI biotech index down 13% for the year, every M&A deal helps improve sentiment, but this one — maybe just a little. Bristol is paying $4.8 billion in cash to acquire Mirati, or $3.7 billion after accounting for Mirati’s cash. It’s a small bolt-on acquisition for Bristol, which isn’t overpaying.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： The surgeon had a dilemma only a Nazi medical text could resolve

WSS

Dewpoint Therapeutics lays off staff after losing partnerships

STAT Virtual Event: The State of Biosimilars: What to Watch

New brain studies show LSD's effects on the brain in full color

Humana cuts profit projections as Medicare Advantage costs soar

Medicare to cover more brain scans for Alzheimer’s patients

Elizabeth Holmes banned from government health programs

leisure time

comprehensive

Wikipedia

DIEP, the 'gold standard' of breast reconstruction, is under threat

Custom gene therapy hints at new path for rare disease treatments

Medicare proposal to cover medical devices draws a mixed reaction

AI generated plenty of interest at JPM but not a lot of trust

Jerome Adams on the need for new antivirals for Covid

Readout Newsletter: Merck, J&J, and long Covid

State Dept. review finds Biden bears some blame for Afghanistan failures

STAT Virtual Event: The State of Biosimilars: What to Watch

Trump demands the U.S. pay no more for drugs than other countries … again

Listen: Wegovy in the brain & pivotal Alzheimer's data

leisure time

How digital therapeutics firms are pivoting after Pear's bankruptcy

Parkinson’s finding may lead to tests and, someday, treatments

Listen: Wegovy in the brain & pivotal Alzheimer's data

New brain studies show LSD's effects on the brain in full color

STAT Virtual Event: The State of Biosimilars: What to Watch

Sanders adds drug shortage policies to pandemic preparedness bill

knowledge

explore

focus

focus